Clinical Trial Update: A Study of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-1088-002) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study of MK-1088, both as monotherapy and in combination with pembrolizumab, in adults with advanced solid tumors was terminated, and results have b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• MK-1088

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Advanced Solid Tumors | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-10-04